Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Open-labelled, Single Dose, Dose-escalation Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pegylated Long-acting Human Growth Hormone (NNC126-0083) Compared to Norditropin NordiFlex® in Growth Hormone Deficient Children

NCT00936403 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00936403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00936403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Open-labelled, Single Dose, Dose-escalation Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pegylated Long-acting Human Growth Hormone (NNC126-0083) Compared to Norditropin NordiFlex® in Growth Hormone Deficient Children
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2009
Completion date
July 31, 2010
Enrollment
31 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

growth hormone deficiency in children, growth hormone disorder